Akero Therapeutics Q1 2025 Update
| Field | Detail |
|---|---|
| Company | Akero Therapeutics, Inc. |
| Form Type | 10-Q |
| Filed Date | May 12, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech, equity-offering
TL;DR
Akero Q1 2025: Raised cash via stock sales & warrants, funding R&D.
AI Summary
Akero Therapeutics, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported on its financial position and business operations. Key financial activities during the quarter included common stock issuances under its ATM program and transactions related to pre-funded warrants. The filing also references various agreements and plans, including the Stock Option and Grant Plan of 2018 and a Loan and Security Agreement from June 15, 2022.
Why It Matters
This filing provides insight into Akero Therapeutics' financial health and ongoing capital-raising activities, which are crucial for funding its drug development pipeline.
Risk Assessment
Risk Level: medium — Biotech companies like Akero Therapeutics face inherent risks related to drug development, clinical trials, and regulatory approvals, which can significantly impact financial performance.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial information is reported.)
- 2025-01-01 — Reporting Period Start Date (Indicates the beginning of the fiscal quarter for which financial information is reported.)
- 2024-03-31 — Prior Year Quarter End Date (Provides a comparative point for financial performance analysis.)
Key Players & Entities
- Akero Therapeutics, Inc. (company) — Filer of the 10-Q report
- March 31, 2025 (date) — End of the reporting period
- 20250331 (date) — Conformed period of report
- 601 GATEWAY BOULEVARD, SUITE 350 (address) — Business and mailing address
- SOUTH SAN FRANCISCO, CA (location) — City and State of business address
- 0000950170-25-068563 (accession_number) — Unique identifier for the filing
- Stock Option and Grant Plan of 2018 (plan) — Referenced equity incentive plan
- Loan and Security Agreement (agreement) — Mentioned financing agreement dated June 15, 2022
- Jeffries (company) — Mentioned in relation to a date of May 16, 2023
FAQ
What were the primary financial activities of Akero Therapeutics during the quarter ending March 31, 2025?
The company engaged in common stock issuances under its ATM program and transactions related to pre-funded warrants during the period from January 1, 2025, to March 31, 2025.
What is the business address of Akero Therapeutics?
The business address is 601 Gateway Boulevard, Suite 350, South San Francisco, CA 94080.
When was the Stock Option and Grant Plan of 2018 established?
The Stock Option and Grant Plan of 2018 was established on June 18, 2019.
Does the filing mention any specific financing agreements?
Yes, the filing references a Loan and Security Agreement dated June 15, 2022.
What is the SIC code for Akero Therapeutics?
The Standard Industrial Classification (SIC) code for Akero Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 12, 2025 regarding Akero Therapeutics, Inc..